Philadelphia Startup Received Funding for Hemorrhage Tech
A new AI-driven heart rate tool aims to help Philadelphia families by improving postpartum hemorrhage detection.
Updated on Sept. 30, 2026 in Pregnancy
Live Poll
Should hospitals prioritize medical technologies designed for existing equipment to lower healthcare costs?
Philadelphia-based Vasowatch has secured a $250,000 investment from the University of Pennsylvania StartUP Fund to advance its postpartum hemorrhage detection technology. The software is designed to analyze heart rate data to identify risks and alert hospital staff earlier.
Why it matters
The technology aims to reduce the risk of life-threatening blood loss by addressing the delayed recognition of hemorrhage, which causes nearly 43,000 deaths annually worldwide. By integrating with existing hospital hardware, the system is designed to provide safer care while lowering costs.
Vasowatch received a $250,000 investment from the University of Pennsylvania StartUP Fund, which has a total pool of $10 million. Postpartum hemorrhage affects approximately 27 million women annually, leading to 43,000 deaths each year.
The players
Vasowatch
A Philadelphia-based health technology company developing heart rate analysis tools to monitor and alert medical staff about postpartum hemorrhage risks.
University of Pennsylvania
An Ivy League research institution that launched a $10 million StartUP Fund to support student and alumni-led medical and technological innovations.
The details
The Vasowatch system works by continuously analyzing heart rate data from standard hospital monitoring devices. By detecting subtle patterns that indicate hemorrhage risk, the software triggers timely alerts to medical staff. This approach allows hospitals to identify emergencies faster without the need to replace existing patient hardware, keeping hospital costs managed while improving patient safety outcomes.
Timeline
January 2027: Planned start for the pivotal clinical trial.
Mid-2028: Target date for expected FDA authorization of the algorithm.
The Home Front
This development follows the trend of integrating diagnostic AI into standard maternal care to improve outcomes. It sits within the broader regulatory framework set by the FDA for approving software as a medical device to ensure safety in hospital settings.
If you are planning for delivery at Pennsylvania Hospital, you may see expanded use of heart rate monitoring software as research continues. Families should consult with their obstetrician about the latest standard monitoring protocols available at their specific local delivery center.
The takeaway
Advancements in maternal care are increasingly moving toward automated, heart-rate-based monitoring to improve safety during childbirth. As these technologies enter hospitals, keep questions about standardized monitoring technology on your list for your next prenatal checkup with your care provider.
What happens next
Vasowatch plans to begin its pivotal clinical trial in January 2027, followed by an aim for FDA authorization of its postpartum hemorrhage prediction algorithm in mid-2028.
Further reading
For more information on innovations in maternal health, visit the Pregnancy section.
Source note: This article includes information reported by Technical.
Live Poll
Should hospitals prioritize medical technologies designed for existing equipment to lower healthcare costs?
